---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-21-048256"
form_type: "8-K"
ticker: "CELU"
cik: "0001752828"
company_name: "Celularity Inc"
filed_at: "2021-09-15T23:59:59+00:00"
generated_at: "2026-06-29T03:35:30.886004+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Celularity appoints Andrew Pecora as President; Hariri remains CEO and Chairman

## Summary
- Andrew Pecora named President effective Sept 15, 2021, replacing Robert Hariri who stays CEO/Chairman.
- Pecora receives $900K base salary, 60% target bonus, and a signing bonus of $1.2M paid in four installments.
- Granted option to purchase 2,469,282 shares, vesting upon achievement of share price targets over up to five installments.
- Pecora previously served as consultant and on Sci Advisory Board; related party transactions with COTA and son's employment disclosed.
- Employment at-will; severance includes nine months' salary (or 12 months after change in control) and COBRA coverage.

## SEC filing metadata
- accession: 0001213900-21-048256
- form_type: 8-K
- ticker: CELU
- cik: 0001752828
- company_name: Celularity Inc
- filed_at: 2021-09-15T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/0001213900-21-048256-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/ea147489-8k_celularity.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-21-048256
- JSON: https://secwatch.observer/filing/0001213900-21-048256.json
- Plain text: https://secwatch.observer/filing/0001213900-21-048256.txt

## Key facts
- Executive change
  Andrew L. Pecora, M.D. was appointed as President at Celularity Inc.
  - Action: appointed
  - Role: President
  source text: appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/0001213900-21-048256-index.htm
- Executive change
  Robert J. Hariri, M.D., Ph.D. changed role as Chief Executive Officer and Chairman of the Board at Celularity Inc.
  - Action: replaced as President
  - Role: Chief Executive Officer and Chairman of the Board
  source text: appointed Andrew L. Pecora, M.D., as President of the Company effective September 15, 2021, replacing Robert J. Hariri, M.D., Ph.D., in this role as of such date.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1752828/000121390021048256/0001213900-21-048256-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.